# MODULO BIO, INC.: The Therapeutic Development of a Clinical NR1H3 Antisense Oligonucleotide to Reprogram Microglia into a Neuroprotective State in ALS and FTD

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | MODULO BIO, INC. |
| Location | San Diego, CA |
| Project | The Therapeutic Development of a Clinical NR1H3 Antisense Oligonucleotide to Reprogram Microglia into a Neuroprotective State in ALS and FTD |
| Project number | 1R44NS143633-01A1 |
| Mechanism | R44 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $847,695 |
| Awarded | 2026-09-19 |
| Project period | 2026-09-21 to 2028-08-31 |
| UEI | U1TNJGPGNHA9 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11409366). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.